Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 3/20 | 0.57 |
| ▸ | MPI | P34949 | 1/20 | 0.57 |
| ▸ | PGK1 | P00558 | 1/20 | 0.50 |
| ▸ | PGK2 | P07205 | 1/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.38 |
| ▸ | SGPL1 | O95470 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20455444 | 1.00 | PGD (0.57) | PGDMPIPGK1PGK2LPAR5 | |
| SCHEMBL3744708 | 1.00 | PGD (0.57) | PGDMPIPGK1PGK2LPAR5 | |
| SCHEMBL5081076 | 1.00 | PGD (0.57) | PGDMPIPGK1PGK2LPAR5 | |
| SCHEMBL14941155 | 1.00 | PGD (0.57) | PGDMPIPGK1PGK2LPAR5 | |
| E968 SCHEMBL18341348 | 1.00 | PGD (0.57) | PGDMPIPGK1PGK2LPAR5 | |
| SCHEMBL18341438 | 1.00 | PGD (0.57) | PGDMPIPGK1PGK2LPAR5 | |
| E968 SCHEMBL18341349 | 1.00 | PGD (0.57) | PGDMPIPGK1PGK2LPAR5 | |
| Phosphoric Acid SCHEMBL18341414 | 0.98 | PGD (0.55) | PGDMPIPGK1PGK2LPAR5 | |
| SCHEMBL18341413 | 0.90 | PGD (0.67) | PGDMPIPGK1PGK2LPAR5 | |
| SCHEMBL18341350 | 0.90 | PGD (0.67) | PGDMPIPGK1PGK2LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594520-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2025-08-06 | — | — | EP | claimed |
| WO-2024069235-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2024-04-04 | — | — | WO | claimed |
| WO-2013133772-A1 | AN INTEGRATED SOLID PHASE EXTRACTION COUPLED ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (SPE-UPLC-MS) METHOD FOR THE PROFILING OF DXP METABOLITES AND SYSTEM DIAGNOSTICS OF DXP PATHWAY | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-09-12 | — | — | WO | claimed |
| WO-2013071074-A1 | METHODS OF PRODUCING BUTADIENE | INVISTA NORTH AMERICA S.A. R.L. (US) | 2013-05-16 | — | — | WO | claimed |
| WO-2012177710-A1 | MICROORGANISMS FOR PRODUCING BUTADIENE AND METHODS RELATED THERETO | GENOMATICA, INC. (US) | 2012-12-27 | — | — | WO | claimed |
| CN-122095083-A | Genetically modified yeasts and fermentation processes for the production of xylitol | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4705429-A1 | GENETICALLY MODIFIED YEAST AND FERMENTATION PROCESSES FOR THE PRODUCTION OF XYLITOL | Cargill, Incorporated (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705495-A2 | METHODS FOR IMPROVED CELL CULTURE PERFORMANCE AND PRODUCT RECOVERY | Amyris, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025230689-A1 | GENETICALLY MODIFIED YEAST AND FERMENTATION PROCESSES FOR THE PRODUCTION OF XYLITOL | CARGILL, INCORPORATED (US) | 2025-11-06 | — | — | WO | disclosed |
| US-20250311723-A1 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | IMPELLO BIOSCIENCES, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4627098-A1 | COMPOSITIONS AND METHODS FOR USING PREVIOUSLY CULTURED CELLS | Amyris Bio Products Portugal, Unipessoal, LDA (PT) | 2025-10-08 | — | — | EP | disclosed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| EP-1198575-A1 | ISOPRENOID BIOSYNTHESIS | Bacher, Adelbert (DE) | 2002-04-24 | — | — | EP | disclosed |
| WO-2002011673-A2 | METHODS OF MODULATING ACTIVITY OF DXR | SMITHKLINE BEECHAM CORPORATION (US) | 2002-02-14 | — | — | WO | disclosed |
| WO-2001094561-A2 | THE NON-MEVALONATE ISOPRENOID PATHWAY | BACHER ADELBERT (DE) | 2001-12-13 | — | — | WO | disclosed |
| EP-1141379-A1 | SCREENING FOR INHIBITORS OF TERPENOIDS BIOSYNTHESIS | Bacher, Adelbert (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001016357-A2 | NOVEL TARGET FOR ANTIPARASITIC AGENTS AND INHIBITORS THEREOF | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2001-03-08 | — | — | WO | disclosed |
| EP-1081232-A1 | Novel target for antifungals | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2001-03-07 | — | — | EP | disclosed |
| WO-2001011055-A1 | ISOPRENOID BIOSYNTHESIS | BACHER ADELBERT (DE) | 2001-02-15 | — | — | WO | disclosed |
| WO-2000036138-A1 | SCREENING FOR INHIBITORS OF TERPENOIDS BIOSYNTHESIS | BACHER ADELBERT (DE) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250311723-A1 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | ERG28, AHCY, BROX | PGD 460/4885MPI 665/4885PGK1 693/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | PGD 4145/4885MPI 2897/4885PGK1 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.